Analysts expect Immatics (NASDAQ:IMTX) to post ($0.33) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Immatics’ earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.33). Immatics posted earnings of $0.06 per share during the same quarter last year, which suggests a negative year over year growth rate of 650%. The business is scheduled to issue its next quarterly earnings results on Wednesday, November 25th.
On average, analysts expect that Immatics will report full year earnings of ($1.28) per share for the current year, with EPS estimates ranging from ($1.53) to ($1.06). For the next fiscal year, analysts expect that the business will post earnings of ($1.32) per share, with EPS estimates ranging from ($1.54) to ($1.17). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Immatics.
Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Thursday, September 3rd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.20). The firm had revenue of $7.70 million for the quarter, compared to the consensus estimate of $8.49 million.
A number of research firms have recently commented on IMTX. Bank of America began coverage on shares of Immatics in a research report on Friday. They issued a “buy” rating and a $13.00 price objective for the company. The Goldman Sachs Group initiated coverage on shares of Immatics in a research report on Monday, September 21st. They issued a “buy” rating and a $17.00 price objective for the company. Zacks Investment Research upgraded shares of Immatics from a “sell” rating to a “hold” rating in a research report on Thursday, November 5th. Chardan Capital reiterated a “buy” rating and set a $28.00 target price on shares of Immatics in a research report on Tuesday, August 18th. Finally, SVB Leerink initiated coverage on shares of Immatics in a research report on Monday, July 27th. They set an “outperform” rating and a $17.00 target price for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $17.80.
IMTX stock opened at $10.50 on Tuesday. The company has a 50 day moving average price of $10.80. Immatics has a 12 month low of $8.66 and a 12 month high of $17.48.
Institutional investors have recently made changes to their positions in the business. Morgan Stanley bought a new stake in Immatics during the third quarter valued at approximately $99,000. GWM Advisors LLC purchased a new position in shares of Immatics during the third quarter worth approximately $106,000. LPL Financial LLC purchased a new position in shares of Immatics during the third quarter worth approximately $115,000. Granite Point Capital Management L.P. purchased a new position in shares of Immatics during the third quarter worth approximately $150,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Immatics during the third quarter worth approximately $222,000. Institutional investors and hedge funds own 50.49% of the company’s stock.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Article: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.